1. Introduction {#sec1-ijerph-17-01815}
===============

Acute respiratory distress syndrome (ARDS) is defined as respiratory failure caused by an acute onset of hypoxemia and bilateral pulmonary infiltrates \[[@B1-ijerph-17-01815],[@B2-ijerph-17-01815],[@B3-ijerph-17-01815]\]. The incidence of ARDS among patients in the intensive care unit (ICU) is 10.4% \[[@B4-ijerph-17-01815]\], and associated mortality has been reported as 11--87% \[[@B5-ijerph-17-01815]\]. According to previous reports, the global burden of ARDS is highest in high- and upper-middle-income countries; the syndrome is an important global health issue \[[@B6-ijerph-17-01815],[@B7-ijerph-17-01815]\].

Given the high mortality risk associated with ARDS, treatment for the disease requires an ICU admission, resulting in an average daily cost of \$2100 per patient, and mean total annual cost at 1 year of \$53,300 \[[@B8-ijerph-17-01815]\]. Previous studies have shown that patients' economic status might affect their mortality risk within an ICU \[[@B9-ijerph-17-01815],[@B10-ijerph-17-01815]\]; it follows that the risk of ARDS-specific mortality might be influenced by each patient's income. In fact, previous studies have reported that economic status might affect mortality risk associated with chronic lung diseases such as asthma \[[@B11-ijerph-17-01815]\] and cystic fibrosis \[[@B12-ijerph-17-01815]\]. Moreover, Bime et al. showed that household income reported for patients' ZIP codes was associated with in-hospital mortality due to severe acute respiratory failure in the United States \[[@B13-ijerph-17-01815]\]. Furthermore, a prospective cohort study from the LUNG SAFE trial has shown that income per person was associated with ARDS outcomes \[[@B14-ijerph-17-01815]\]. However, these findings might be mediated by the structure of each country's health insurance system; further research is required to elucidate the link between patients' income and the risk of ARDS-associated mortality. In South Korea, individuals are generally registered in the National Health Insurance Service (NHIS) as a requirement and income levels of all individuals are recorded accurately on the first day of each month to determine insurance fees for all individuals \[[@B15-ijerph-17-01815]\].

This study aimed to investigate any association between the income level of ARDS patients at the time of diagnosis and their mortality risk after initiation of ARDS treatment. We hypothesized that a lower income level might be associated with a higher mortality risk among ARDS patients.

2. Materials and Methods {#sec2-ijerph-17-01815}
========================

2.1. Ethical Statement {#sec2dot1-ijerph-17-01815}
----------------------

All procedures performed on human participants were in accordance with the ethical standards of the institutional and/or national research committee (Seoul National University Bundang Hospital (X-1903-531-902) and the Health Insurance Review and Assessment Service (NHIS-2019-1-274).

2.2. Data Source {#sec2dot2-ijerph-17-01815}
----------------

We used health records from the national database of South Korea, provided by the National Health Insurance Service (NHIS). The NHIS, which is the nation's key health-protecting institution, is responsible for the management of national health insurance, which provides disease-related and long-term care, ensuring comfortable aging. In South Korea, data on all diagnoses of disease alongside prescription information (including drugs and procedures) are included in the NHIS database. Additionally, the population's annual income level is registered by the NHIS, as it is used to determine insurance fees. However, despite differences in fees, Koreans tend to receive similar coverage from the NHIS, which is equivalent to approximately 2/3's of the co-payment for total hospital charges. Furthermore, if patients cannot afford their insurance premium or face financial difficulties, the government covers almost all their medical expenses. For the purpose of this study, data extraction was performed by a medical records technician at the NHIS center.

2.3. Study Population {#sec2dot3-ijerph-17-01815}
---------------------

All adult patients (≥18 years old) admitted to a hospital for ARDS-related treatment (International Classification of Diseases; ICD-10 codes of J80\*) from 1 January 2013, to 31 December 2017, were included in this study. In cases of multiple admissions (≥2) for ARDS-related treatment per patient, only the most recent admission was included in the analysis. Additionally, cases with incomplete or missing data on income level were excluded.

2.4. Income Level as An Independent Variable {#sec2dot4-ijerph-17-01815}
--------------------------------------------

Using the NHIS database, income levels of ARDS patients in the year of diagnosis and treatment were evaluated. Annual income of patients at the time of diagnosis of ARDS was divided into four groups (Q1--Q4), using quartile ratios.

2.5. Study Endpoint {#sec2dot5-ijerph-17-01815}
-------------------

The primary endpoint was the 30-day or 1-year mortality rate, following initiation of ARDS treatment. Mortality data were extracted until 30 May 2019. Survival time was calculated from the date of initial ARDS treatment to the date of death, or 30 May 2019, for ARDS survivors.

2.6. Confounders {#sec2dot6-ijerph-17-01815}
----------------

The data collected as confounders for this study included demographic characteristics (age and gender) and place of residence at the time of diagnosis of ARDS (Seoul, metropolitan cities, and other). In the classification of residence, Seoul, the capital city, was assigned a separate category, and the cities of Incheon, Kwangju, Busan, Ulsan, Daegu, and Daejeon were classified as metropolitan cities. Comorbidities before diagnosis of ARDS were considered under corresponding ICD-10 codes (hypertension (I10--I16), diabetes mellitus (E10--E14), coronary artery disease (I20\*--I25\*), cerebrovascular disease (I60\*--I69\*), lung cancer (C30--C39), chronic kidney disease (N18\*), dyslipidemia (E78.0), anemia (D64\*), chronic obstructive lung disease (J44\*), asthma (J45\*), arrhythmia (I49\*), and liver cirrhosis (K74\*)). Extracorporeal membrane oxygenation (ECMO), as part of ARDS treatment, was also considered.

2.7. Statistical Analysis {#sec2dot7-ijerph-17-01815}
-------------------------

Baseline characteristics of the ARDS patients were presented as means and standard deviations (SD) for continuous variables and counts with percentages for categorical variables. We performed a multivariable Cox regression analysis for two dependent variables (30-day mortality and 1-year mortality). All covariates (age, gender, place of residence, and comorbidities before ARDS diagnosis) were included in these multivariable models. It was confirmed that there was no multi-collinearity in any multivariable model with variance inflation factors \<2.0, and a log--log plot was used to confirm that the central assumption of each multivariable model was satisfied. In addition, the C-statistic was used to investigate the goodness-of-fit of the multivariable models for predicting 30-day and 1-year mortality, following ARDS treatment; these findings were reported as a C-index with the corresponding 95% confidence interval (CI). The Cox regression model was presented as a hazard ratio (HR) with 95% CIs. Finally, a survival plot derived from the multivariable Cox regression model for 1-year mortality was presented according to the four groups of income levels. All analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA), and a *p* \< 0.05 was considered statistically significant.

3. Results {#sec3-ijerph-17-01815}
==========

3.1. Patients {#sec3dot1-ijerph-17-01815}
-------------

From 1 January 2013, to 31 December 2017, 14,921 adult patients were admitted to the ICU 17,022 times for treatment of ARDS in South Korea. Among them, 2101 admissions were excluded, as they were multiple (≥2) admissions of the same patient. Of the included patients, 321 patients were excluded due to incomplete income information at diagnosis of ARDS. Finally, 14,600 ARDS patients were included in the analysis. Among them, 7100 patients (48.6%) and 10,259 patients (70.3%) died within 30-days and 1-year after initiation of ARDS treatment, respectively ([Figure 1](#ijerph-17-01815-f001){ref-type="fig"}). The baseline characteristics of South Korean ARDS patients are presented in [Table 1](#ijerph-17-01815-t001){ref-type="table"}. The mean length of hospital stay among these patients was 16.2 days (SD: 15.0 days), and the mean duration of treatment was 18.4 days (SD: 17.1 days). Meanwhile, 681 patients (4.7%) were treated using ECMO.

3.2. Survival Analysis According to Income Level {#sec3dot2-ijerph-17-01815}
------------------------------------------------

[Table 2](#ijerph-17-01815-t002){ref-type="table"} shows the results of the multivariable Cox regression models for 30-day and 1-year mortality in the ARDS patients according to income level. Using Q1 income level as a reference, Q2 (HR = 1.02, 95% CI: 0.94--1.10; *p* = 0.719), Q3 (HR = 1.00, 95% CI: 0.93--1.08; *p* = 0.946), and Q4 (HR = 0.98, 95% CI:0.91--1.05; *p* = 0.542) income levels were not associated with the risk of 30-day mortality. Similarly, with the same reference, income levels Q2 (HR = 0.99, 95% CI: 0.93--1.06; *p* = 0.762), Q3 (HR = 0.98, 95% CI: 0.92--1.04; *p* = 0.420), and Q4 (HR = 0.96, 95% CI: 0.91--1.02; *p* = 0.189) were not associated with the risk of 1-year mortality. The C-index for the 30-day mortality was 0.76 (95% CI: 0.75--0.77), and for the 1-year mortality it was 0.90 (95% CI: 0.89--0.91). The survival plot derived from the multivariable Cox regression model is presented in [Figure 2](#ijerph-17-01815-f002){ref-type="fig"}, showing a similar survival trend in the 20 strata of income.

4. Discussion {#sec4-ijerph-17-01815}
=============

This nationwide cohort study from South Korea has shown that income level at diagnosis of ARDS was not significantly associated with the risk of 30-day or 1-year mortality following initiation of ARDS treatment. Our results suggest that economic status prior to diagnosis of ARDS is not a significant factor when considering the prognosis of ARDS patients treated within the NHIS system of South Korea. These findings are important, as the NHIS system in South Korea covers 2/3's of the total medical costs for the general population \[[@B15-ijerph-17-01815]\], increasing the coverage to 100% for groups that require financial support \[[@B16-ijerph-17-01815]\]. In contrast to previous studies reporting on the impact of individuals' income on their ARDS-related prognosis within different health insurance systems \[[@B13-ijerph-17-01815],[@B14-ijerph-17-01815]\], we present evidence that income might not be an important prognostic factor for ARDS patients, given suitable public health insurance coverage.

Our results are different from those of a similar previous study by Bime et al. \[[@B13-ijerph-17-01815]\], which has shown that median household income reported for patients' ZIP codes was associated with in-hospital mortality in patients with severe acute respiratory failure. The study by Bime and colleagues analyzed data from patients with severe acute respiratory failure diagnosed during 2008--2012, using the ICD-9 diagnostic system; in contrast, our study used data from patients with ARDS diagnosed during 2013--2017, using the ICD-10 diagnostic system. Since the Berlin definition of ARDS was developed in 2012 by the ARDS task force \[[@B3-ijerph-17-01815]\], the ARDS patients in our nationwide study might have been diagnosed based on different criteria compared with the study by Bime et al. Considering that the incidence of ARDS might be underestimated when based on the ICD-9 diagnostic system \[[@B17-ijerph-17-01815]\], our results are likely more reliable than the previously reported results. Furthermore, the accuracy of income level data in our study is higher, as data on income levels of all ARDS patients were extracted from the NHIS database.

The results in our study might be influenced by ARDS being the most fatal clinical syndrome. Since the mortality of ARDS has been reported as 87% in previous studies \[[@B5-ijerph-17-01815]\], the impact of economic status on mortality risk might be limited. Furthermore, most critically ill patients in South Korea might be treated with a similar level of care, as 2/3's of treatment costs are covered by the NHIS \[[@B15-ijerph-17-01815]\]. Therefore, the results in this study might differ from results reported for countries where the government does not pay for healthcare to a similar extent. While evidence is insufficient regarding the association between income, insurance status, and ARDS-related mortality in other countries, previous studies have shown that a lack of insurance is associated with a higher mortality rate among critically ill patients with sepsis \[[@B18-ijerph-17-01815],[@B19-ijerph-17-01815]\], which is a comparably critical illness. Therefore, more studies are needed to confirm the association between economic status and ARDS-specific mortality risk in different insurance settings.

The present study reported on 30-day and 1-year mortality, because we had survival time data for all ARDS patients followed-up for at least 365 days. The 1-year mortality rate among ARDS patients might be a measure of long-term outcomes. Previous studies have reported that ARDS survivors commonly suffer from persistent functional disability 1 to 5 years after ICU discharge \[[@B20-ijerph-17-01815],[@B21-ijerph-17-01815]\]. Recovery after ICU discharge among ARDS patients is an important challenge \[[@B22-ijerph-17-01815]\]. In fact, studies have shown that most ARDS survivors have lost their previous job and never resume employment post-discharge \[[@B23-ijerph-17-01815],[@B24-ijerph-17-01815]\]. Critically ill patients in the United States who do not have health insurance receive fewer critical care services and may experience worse clinical outcomes \[[@B25-ijerph-17-01815]\]. From these perspectives, our study has shown that financial support provided by the government as national insurance reduces the impact of personal income on relatively long-term mortality. Financial support might be needed for ARDS patients with a lower economic status to ensure their health prognoses are similar to the prognoses of people within higher economic strata.

This study has several limitations. First, some important information, such as body mass index, was not included in the analysis because the NHIS database does not provide this information. Second, we used the ICD-10 codes registered in the NHIS database to define comorbidities. The diseases specified in the ICD-10 codes may have differed from the actual underlying diseases. Third, there might be some ARDS patients not registered as having ARDS under the ICD-10 diagnostic system (J80\*). Fourth, we did not consider some important characteristics of ARDS patients, such as the P/F ratio, simplified acute physiology score-II, and the acute physiology and chronic health evaluation II score, which are closely related to patient prognosis; these data were not available from the NHIS database. Lastly, since this study was based on a retrospectively collected dataset, there might be residual confounders that might affect the results of this study.

5. Conclusions {#sec5-ijerph-17-01815}
==============

This nationwide cohort study showed that income level before ARDS diagnosis was not significantly associated with 30-day and 1-year mortality among ARDS patients captured by the NHIS coverage system in South Korea. These findings suggest that individuals' economic status might not be an important prognostic factor for ARDS, given suitable public health insurance coverage. Well-designed and prospective cohort studies should be performed to confirm these findings in other countries with different insurance systems.
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ijerph-17-01815-t001_Table 1

###### 

Baseline characteristics of acute respiratory distress syndrome (ARDS) patients in South Korea from 2013 to 2017.

  Variable                         Total (14,600), n (%)         Mean (SD)     
  -------------------------------- ----------------------------- ------------- --
  Age, year                                                      69.8 (15.3)   
  Gender, male                     9065 (62.1)                                 
  Residence at diagnosis                                                       
                                   Capital city, Seoul           2402 (16.5)   
                                   Other metropolitan city ^a^   3334 (22.8)   
                                   Others                        8864 (60.7)   
  Income level at diagnosis                                                    
                                   Q1                            2449 (16.8)   
                                   Q2                            2732 (18.7)   
                                   Q3                            4199 (28.8)   
                                   Q4                            5220 (35.8)   
  Length of hospital stay, day                                   16.2 (15.0)   
  Duration of treatment, day                                     18.4 (17.1)   
  ECMO use for treatment           681 (4.7)                                   
  Comorbidities before diagnosis                                               
                                   Hypertension                  9735 (66.7)   
                                   Coronary artery disease       4403 (30.2)   
                                   Diabetes mellitus             6500 (44.5)   
                                   Cerebrovascular disease       5044 (34.5)   
                                   Lung cancer                   1125 (7.7)    
                                   Chronic kidney disease        1434 (9.8)    
                                   Dyslipidemia                  8021 (54.9)   
                                   Anemia                        2733 (18.7)   
                                   COPD                          3819 (26.2)   
                                   Asthma                        1809 (12.4)   
                                   Arrhythmia                    1017 (7.0)    
                                   Liver cirrhosis               408 (2.8)     
  Diagnosis per year                                                           
                                   2013                          1978 (13.5)   
                                   2014                          2089 (14.3)   
                                   2015                          2065 (14.1)   
                                   2016                          2289 (15.7)   
                                   2017                          6179 (42.3)   

Metropolitan city ^a^ include Incheon, Kwangju, Busan, Ulsan, Daegu, and Daejeon. ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; COPD, chronic obstructive pulmonary disease.
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###### 

Multivariable Cox regression model for 30-day and 1-year mortality according to income level.

  Variable                         30-Day Mortality          *p*                 1-Year Mortality    *p*                 
  -------------------------------- ------------------------- ------------------- ------------------- ------------------- ---------
  Income level at ARDS diagnosis                                                                                         
                                   Q1                        1                                       1                   
                                   Q2                        1.02 (0.94, 1.10)   0.719               0.99 (0.93, 1.06)   0.762
                                   Q3                        1.00 (0.93, 1.08)   0.946               0.98 (0.92, 1.04)   0.420
                                   Q4                        0.98 (0.91, 1.05)   0.542               0.96 (0.91, 1.02)   0.189
  Age, year                        1.02 (1.01, 1.02)         \<0.001             1.02 (1.01, 1.02)   \<0.001             
  Gender, male                     1.00 (0.95, 1.05)         0.895               1.03 (0.99, 1.07)   0.167               
  Residence at diagnosis                                                                                                 
                                   Capital city, Seoul       1                                       1                   
                                   Other metropolitan city   1.18 (1.09, 1.27)   \<0.001             1.12 (1.06, 1.20)   \<0.001
                                   Others                    1.11 (1.04, 1.19)   0.002               1.04 (0.98, 1.09)   0.211
  ECMO use for treatment           1.30 (1.16, 1.45)         \<0.001             1.38 (1.25, 1.52)   \<0.001             
  Comorbidity before diagnosis                                                                                           
                                   Hypertension              0.92 (0.87, 0.97)   0.004               0.93 (0.89, 0.97)   0.002
                                   Coronary artery disease   0.97 (0.92, 1.03)   0.285               0.95 (0.91, 1.00)   0.029
                                   Diabetes mellitus         0.99 (0.94, 1.04)   0.687               0.98 (0.94, 1.02)   0.397
                                   Cerebrovascular disease   0.89 (0.84, 0.94)   \<0.001             0.93 (0.89, 0.97)   0.002
                                   Lung cancer               0.99 (0.91, 1.08)   0.799               1.09 (1.02, 1.17)   0.017
                                   Chronic kidney disease    0.80 (0.73, 0.87)   \<0.001             0.84 (0.78, 0.90)   \<0.001
                                   Dyslipidemia              1.06 (1.00, 1.12)   0.039               1.07 (1.02, 1.12)   0.004
                                   Anemia                    0.94 (0.88, 1.00)   0.050               0.95 (0.87, 1.03)   0.182
                                   COPD                      0.76 (0.71, 0.80)   \<0.001             0.77 (0.74, 0.81)   \<0.001
                                   Asthma                    0.98 (0.90, 1.06)   0.539               0.96 (0.90, 1.02)   0.194
                                   Arrhythmia                0.95 (0.86, 1.05)   0.332               0.95 (0.87, 1.03)   0.182
                                   Liver cirrhosis           1.17 (1.01, 1.34)   0.034               1.17 (1.04, 1.31)   0.010
  Diagnosis per year                                                                                                     
                                   2013                      1                                       1                   
                                   2014                      0.86 (0.80, 0.93)   \<0.001             0.84 (0.78, 0.89)   \<0.001
                                   2015                      0.84 (0.78, 0.91)   \<0.001             0.76 (0.72, 0.82)   \<0.001
                                   2016                      0.79 (0.73, 0.85)   \<0.001             0.70 (0.66, 0.75)   \<0.001
                                   2017                      0.25 (0.23, 0.27)   \<0.001             0.16 (0.15, 0.18)   \<0.001

C-index for 30-day mortality: 0.76 (95% CI: 0.75--0.77); and for 1-year mortality: 0.90 (95% CI: 0.89--0.91). HR, hazard ratio; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; COPD, chronic obstructive pulmonary disease.
